Biogen (BIIB) to Release Quarterly Earnings on Thursday

Biogen (NASDAQ:BIIB - Get Free Report) is expected to be announcing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Biogen to post earnings of $3.89 per share and revenue of $2.3356 billion for the quarter. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.Interested persons are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, beating the consensus estimate of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.32 billion. During the same quarter in the prior year, the company posted $5.28 earnings per share. Biogen's revenue for the quarter was up 7.3% compared to the same quarter last year. On average, analysts expect Biogen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $147.72 on Thursday. Biogen has a one year low of $110.04 and a one year high of $187.58. The stock has a market capitalization of $21.66 billion, a price-to-earnings ratio of 14.12, a PEG ratio of 1.16 and a beta of 0.13. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50. The company has a 50-day simple moving average of $142.50 and a 200-day simple moving average of $131.81.

Insider Activity

In other news, insider Priya Singhal sold 517 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the sale, the insider directly owned 5,772 shares in the company, valued at approximately $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.18% of the company's stock.

Institutional Investors Weigh In On Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Empowered Funds LLC boosted its stake in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company's stock worth $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth grew its position in Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company's stock worth $1,392,000 after purchasing an additional 6,436 shares during the period. Sivia Capital Partners LLC bought a new position in shares of Biogen during the 2nd quarter valued at $216,000. Cerity Partners LLC grew its holdings in shares of Biogen by 15.3% in the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company's stock worth $5,847,000 after acquiring an additional 6,184 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company's stock valued at $336,000 after acquiring an additional 316 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on BIIB shares. Royal Bank Of Canada cut their price target on shares of Biogen from $219.00 to $217.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 8th. Needham & Company LLC reissued a "hold" rating on shares of Biogen in a report on Wednesday, September 24th. Rothschild & Co Redburn boosted their target price on Biogen from $149.00 to $150.00 and gave the company a "neutral" rating in a research note on Monday, October 6th. Wall Street Zen raised Biogen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 28th. Finally, Wedbush upped their price target on shares of Biogen from $129.00 to $135.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 14th. Eleven research analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $180.69.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.